Innovative Pharmaceutical Biotech's market cap is currently HK$328.00M. The company's EPS TTM is HK$0.006; its P/E ratio is 28.57; Innovative Pharmaceutical Biotech is scheduled to report earnings on November 28, 2025, and the estimated EPS forecast is HK$―. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
Income Statement
Total Revenue	HK$ 6.59M	HK$ 8.07M	HK$ 11.14M	HK$ 15.19M	HK$ 14.58M
Gross Profit	HK$ 840.00K	HK$ 858.00K	HK$ 1.05M	HK$ 1.41M	HK$ 1.62M
Operating Income	HK$ -13.43M	HK$ -20.70M	HK$ -24.35M	HK$ -21.34M	HK$ -26.02M
EBITDA	HK$ 317.75M	HK$ -18.82M	HK$ -22.30M	HK$ -18.81M	HK$ -80.49M
Net Income	HK$ 103.40M	HK$ -245.70M	HK$ 296.54M	HK$ -395.75M	HK$ -407.56M
Balance Sheet
Cash & Short-Term Investments	HK$ 3.08M	HK$ 1.33M	HK$ 4.08M	HK$ 8.99M	HK$ 22.94M
Total Assets	HK$ 1.38B	HK$ 1.38B	HK$ 1.39B	HK$ 1.40B	HK$ 1.42B
Total Debt	HK$ 1.01B	HK$ 1.19B	HK$ 941.84M	HK$ 991.48M	HK$ 789.85M
Net Debt	HK$ 1.01B	HK$ 1.19B	HK$ 937.76M	HK$ 982.49M	HK$ 766.91M
Total Liabilities	HK$ 1.06B	HK$ 1.24B	HK$ 999.73M	HK$ 1.04B	HK$ 851.11M
Stockholders' Equity	HK$ -611.51M	HK$ -795.07M	HK$ -549.37M	HK$ -595.35M	HK$ -390.37M
Cash Flow
Free Cash Flow	HK$ -8.28M	HK$ -17.64M	HK$ -12.34M	HK$ -25.01M	HK$ -36.22M
Operating Cash Flow	HK$ -8.28M	HK$ -17.64M	HK$ -12.34M	HK$ -25.01M	HK$ -36.22M
Investing Cash Flow	HK$ 0.00	HK$ 0.00	HK$ -1.00K	HK$ 13.00K	HK$ 49.98M
Financing Cash Flow	HK$ 10.32M	HK$ 14.92M	HK$ 7.30M	HK$ 10.57M	HK$ -9.48M

Currency in HKD

Innovative Pharmaceutical Biotech Earnings and Revenue History

Income Statement >

Innovative Pharmaceutical Biotech Debt to Assets

Balance Sheet >

Innovative Pharmaceutical Biotech Cash Flow

Cash Flow >

Innovative Pharmaceutical Biotech Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing